Table 2.
Effect of OPV on the Rates of Morbidity and Mortality Among Participants in the OPV-COVID Trial in Urban Guinea-Bissau
| Outcome | Rate/100 PYRS (Events/PYRS) | HR (95% CI)a | |
|---|---|---|---|
| OPV | No OPV | ||
| Primary (composite) outcome | 22.7 (169/746) | 23.8 (239/1006) | 0.97 (.79–1.18) |
| Secondary Outcomes | |||
| Mortalityb | 3.6 (28/786) | 3.6 (38/1065) | 0.96 (.59–1.55) |
| Mortality first 3 months | 2.3 (9/394) | 3.4 (18/535) | 0.65 (.29–1.45) |
| Mortality last 3 months | 4.8 (19/392) | 3.8 (20/530) | 1.23 (.66–2.30) |
| Hospital admissions for infection | 4.5 (35/783) | 5.9 (62/1057) | 0.76 (.49–1.17) |
| Recorded consultations for infections | 15.9 (124/782) | 16.4 (174/1058) | 0.99 (.79–1.25) |
| Reported symptoms of infections | 391.3 (2724/696) | 351.7 (3326/946) | 1.10 (1.03–1.17) |
| Reported symptoms of COVID-19 | 20.9 (162/774) | 17.9 (187/1042) | 1.14 (.89–1.47) |
| Reported consultations for infectionsb | 57.6 (442/767) | 50.9 (528/1038) | 1.13 (.99–1.31) |
| Reported consultations for infections first 3 months | 50.3 (194/386) | 51.1 (267/523) | 0.99 (.81–1.20) |
| Reported consultations for infections last 3 months | 65.1 (248/381) | 50.7 (261/515) | 1.29 (1.06–1.55) |
Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; HR, hazard ratio; OPV, oral polio vaccine; PYRS, person-years.
a
Hazard ratio compared in Cox proportional hazards models with time since enrollment as underlying timescale. Adjusted for age and zone of residence.
b
Proportional hazards could not be confirmed for the main analysis.